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diabetic cardiomyopathy; cardiomyocyte apoptosis; verapamil THIOREDOXIN-INTERACTING PROTEIN (TXNIP) has recently been shown to have detrimental effects on the cardiovascular system including oxidative stress, endothelial cell inflammation, and cardiomyocyte apoptosis (25, 29, 33) . In addition, TXNIP expression was increased in cardiomyocytes in response to myocardial infarction (MI) (31) , hypobaric hypoxia (14) , and pressure overload (34) . In contrast, knockdown of TXNIP resulted in reduced apoptosis and fibrosis and prevented left ventricular remodeling and hypertrophy after MI and pressure overload, suggesting that downregulation of TXNIP may offer a novel therapeutic approach to protect cardiomyocytes (31) .
TXNIP is a ubiquitously expressed protein that binds and inhibits thioredoxin and thereby can induce oxidative stress and modulate the cellular redox state (13, 20, 22, 32) . In fact, alterations of the thioredoxin system have been implicated in different cardiovascular diseases, suggesting that endogenous regulators such as TXNIP may represent important therapeutic targets especially in disorders associated with oxidative stress (30) . However, very little is known about the regulation of TXNIP especially in the heart.
In pancreatic beta cells, we have previously shown that TXNIP expression is strongly induced by glucose and by diabetes and that TXNIP overexpression induces apoptosis (18, 19, 26) . In contrast, TXNIP deficiency protected pancreatic beta cells against oxidative stress, glucose toxicity, and apoptosis (4, 6) and even was able to rescue mice from Type 1 and Type 2 diabetes by preserving beta cell mass and function (5) .
The present study was therefore aimed at assessing whether diabetes also induces cardiac TXNIP expression and at identifying pharmacological means to reduce TXNIP expression and apoptosis in the heart.
MATERIALS AND METHODS
Cell culture. H9C2 rat cardiomyocytes (ATCC) were maintained in DMEM modified to contain 4 mM L-glutamine, 4,500 mg/l glucose, 1 mM sodium pyruvate, 1,500 mg/l sodium bicarbonate, 1.8 mM CaCl 2, and 0.8 mM MgCl 2, pH 7.3 and supplemented with 10% FBS. Cells were incubated for 24 h in the absence or presence of verapamil (MP Biomedicals, Irvine, CA) or diltiazem (Sigma). To assess the role of calcium, cells were incubated in media depleted of calcium by pretreatment with the chelator ethylene glycol tetraacetic acid (EGTA, 500 M for 1 h) (Sigma).
Animal studies. All mouse studies were approved by the University of Wisconsin Animal Care and Use Committee and conform with the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health.
Wild-type, 6-to 8-wk-old, male C57BL/6/Sv129 F1 mice (Jackson Laboratory) were rendered diabetic by a single intraperitoneal injection of streptozotocin (STZ; 200 mg/kg) and hyperglycemia of Ͼ300 mg/dl was confirmed after 48 h. Mice were euthanized 4 days after the injection and their hearts were collected for protein and RNA extraction.
As a model of Type 2 diabetes, leptin-deficient, obese, insulinresistant, and diabetic BTBRlep ob/ob (ob/ob) (Jackson Laboratory) were used and compared with lean control BTBR mice. The ob/ob mice develop severe diabetes ϳ6 wk of age and were euthanized at 12 wk for tissue collection (blood glucose Ͼ400 mg/dl).
Mice received verapamil in their drinking water (1 mg/ml) for 3 wk, resulting in an average dose of 100 mg ⅐ kg Ϫ1 ⅐ day Ϫ1 as described previously (7) . Control mice were housed under identical conditions without verapamil. The heart rate and blood pressure of control and verapamil-treated mice were assessed as described previously (3) .
TXNIP-deficient HcB-19 mice and the control C3H/DiSnA strain were a generous gift of Dr. Aldons J. Lusis, UCLA, and have been described previously (2, 5, 11, 27) . In brief, HcB-19 mice represent a recombinant congenic strain that was derived from the C3H/DiSnA strain and was found to harbor a naturally occurring inactivating nonsense mutation in exon 2 at codon 97 of their TXNIP gene, resulting in dramatically reduced, but not absent, TXNIP mRNA and protein levels (2).
Immunoblotting. Protein extracts were prepared using a lysis buffer containing HEPES (50 mM), Nonidet P-40 (10%), sodium fluoride (100 mM), sodium pyrophosphate (10 mM), EDTA (4 mM), PMSF (1 mM), leupeptin (2 M), activated sodium orthovanadate (2 mM), and okadaic acid (100 nM) and were separated by 4 -20% SDS-PAGE and blotted onto polyvinylidene difluoride membranes. Antibodies used were TXNIP (1:400) (JY2, MBL International), cleaved caspase-3 (1:200) (Cell Signaling), ␤-actin (1:200) (Abcam), and anti-mouse IgG (1:5,000) (Amersham). Bands were visualized by Lumigen PS-3 detection reagent (Amersham) and quantified by ImageQuant.
Transfection experiments. H9C2 cells were grown in 12-well plates and transiently transfected with the human TXNIP luciferase reporter construct (0.8 g/well) (18) and pRL-TK (5 ng/well) using Lipofectamine Plus (Invitrogen) and the transcriptional activity of the TXNIP promoter was assessed after 24 h by Dual Luciferase Assay (Promega) and corrected for transfection efficiency by Renilla luciferase.
Quantitative real-time RT-PCR. Mouse heart RNA was isolated using TRIzol (Invitrogen), and 1 g RNA was used for conversion to cDNA by First Strand cDNA Synthesis Kit for RT-PCR (Roche).
Real-time RT-PCR was run on a 7000 Sequence Detection System (Applied Biosystems). Primers for COL1A2 were forward 5Ј-ACGTGCCGGGACTTAAGACTC-3Ј and reverse 5Ј-GTAGTA-ATCGCTGTT CCACTCTGG-3Ј. All other primers have been described previously (4, 18) . TUNEL analysis. Hearts were fixed in 4% formaldehyde and paraffin embedded, and 5-m sections were prepared. The DeadEnd Fluorometric TUNEL System kit (Promega, Madison, WI) was used to detect apoptotic nuclei according to the manufacturer's instructions, but including a permeabilization step (5 min in a 1% Triton X-100 PBS solution). The Vectashield with DAPI mounting solution (Vector, Burlingame, CA) was used for visualization of nuclei.
Statistical analysis. To calculate the significance of a difference between two means, we used Student's t-tests. For data sets of more than two groups we utilized one-way ANOVA calculations. A P value of Ͻ0.05 was considered statistically significant.
RESULTS

Glucose induces cardiomyocyte TXNIP expression.
To investigate whether glucose induces TXNIP expression in cardiomyocytes, we incubated H9C2 cardiomyocytes at low (5 mM) and high (25 mM) glucose for 24 h. We found that glucose induces cardiomyocyte TXNIP protein expression (Ͼ3-fold, P Ͻ 0.01) as measured by immunoblotting (Fig. 1, A and B) and that this induction is mediated by transcriptional activation of the TXNIP promoter as determined by transfection studies (Fig. 1C) . This is consistent with our previous human pancreatic islet microarray study where TXNIP was the most dramatically upregulated gene in response to glucose (26) and with the observation that glucose induces beta cell TXNIP expression at the transcriptional level (18) .
Cardiac TXNIP expression is elevated in diabetes. To test whether cardiac TXNIP expression is also elevated in vivo in diabetes, we measured TXNIP in hearts of mice rendered diabetic by STZ. The results of these studies revealed that TXNIP expression is significantly elevated in diabetic animals ( Fig. 2A) and this increase in TXNIP expression is accompanied by increased apoptosis as measured by cleaved caspase-3 (Fig. 2B) . These effects were even more pronounced in the leptin-deficient, obese, and insulin-resistant ob/ob mice as a model of Type 2 diabetes (Fig. 2, C and D) .
These findings are in agreement with the hyperglycemiainduced increase in vascular TXNIP expression (25) and the TXNIP-mediated apoptosis previously observed in cardiomyocytes (29, 31) and suggest that TXNIP may be involved in the detrimental effects of diabetes on cardiomyocytes. They further raise the possibility that decreasing TXNIP expression may provide cardioprotection, a notion that is supported by the beneficial effects observed with TXNIP deletion in the context of MI and pressure overload (31, 34) . However, to achieve this goal, agents that can lower cardiac TXNIP expression have to be identified.
While studying regulation of TXNIP expression in pancreatic beta cells, we tested different calcium channel blockers in an attempt to block glucose-induced insulin secretion. In the process we noticed that verapamil, and to a lesser degree diltiazem, led to a significant reduction in TXNIP expression in INS-1 beta cells and primary human islets (data not shown). We therefore decided to test whether verapamil could be used to lower cardiac TXNIP expression. Fig. 6 . Verapamil effects on TXNIP expression and apoptosis in the diabetic heart. Wild-type mice were divided into 2 groups (n ϭ 3) and treated with or without verapamil (100 mg/kg po) for a total of 3 wk. Four days prior to euthanasia, mice of both groups were rendered diabetic by STZ injection (200 mg/kg). After euthanasia, their hearts were harvested and assessed for TXNIP (A) and cleaved caspase- 
Calcium channel blockers reduce TXNIP expression in cardiomyocytes.
To assess the effects of verapamil on cardiomyocytes, we incubated H9C2 cells at 25 mM glucose and treated them with different concentrations of verapamil. The results of these experiments demonstrated that verapamil reduces TXNIP expression in a dose-dependent manner in cardiomyocytes (Ͼ5-fold at 100 M) (Fig. 3A) and that this reduction is mediated by decreased transcriptional activity of the TXNIP promoter (Fig. 3B) .
Even though less pronounced, we also observed a reduction in TXNIP expression in response to diltiazem (Fig. 3C ) consistent with our prior INS-1 results. This suggests that the TXNIP-lowering effect is not agent specific, but rather a common feature of calcium channel blockers. To further determine whether changes in intracellular calcium can mimic this effect, we incubated H9C2 cardiomyocytes in the presence of the calcium chelator EGTA. We observed a small but significant 35% reduction in TXNIP expression (P ϭ 0.02) in response to EGTA. This modest effect size may be due to the fact that on the basis of the ionic conditions of our culture media, EGTA may reduce but not completely eliminate calcium. In any case, these results suggest that the TXNIPlowering effects of calcium channel blockers are at least in part mediated by decreased intracellular calcium.
Verapamil administration reduces cardiac expression of TXNIP and cleaved caspase-3 in vivo.
To determine whether verapamil can also reduce cardiac TXNIP in vivo, mice received verapamil in their drinking water for 3 wk; after euthanasia their hearts were analyzed for TXNIP expression as well as for markers of apoptosis and fibrosis at the mRNA and at the protein level. Quantitative real-time RT-PCR revealed a significant decrease in the mRNA expression of TXNIP, caspase-3, and collagen type 1 ␣2 (P Ͻ 0.01) in response to verapamil (Fig. 4, A-C) . Immunoblotting further confirmed these findings (Fig. 4, D-F) , demonstrating that even a short course of oral verapamil administration can inhibit cardiac TXNIP expression and apoptosis and therefore may be cardioprotective. On the other hand, 3 wk of oral verapamil did not lead to any significant changes in body weight, blood glucose, heart rate, or blood pressure (data not shown).
Cleaved caspase-3 expression is reduced in hearts of TXNIPdeficient HcB-19 mice. Although the observed verapamil-induced reduction in cardiac expression of cleaved caspase-3 was associated with decreased TXNIP expression, these findings do not provide direct proof that the effects are mediated by TXNIP. To address this question, we studied hearts of TXNIP-deficient HcB-19 mice. [HcB-19 mice have a naturally occurring inactivating nonsense mutation in the TXNIP gene, resulting in dramatically reduced, but not totally absent, TXNIP mRNA and protein levels (2) .] If TXNIP reduction was responsible for the reduced apoptosis in response to verapamil, TXNIP deficiency should mimic this effect and HcB-19 mice should have lower cardiac expression of cleaved caspase-3. In fact, this is exactly what we observed in our experiments (Fig. 5, A and B) . These findings strongly suggest that TXNIP plays a key role in cardiac apoptosis and that genetic or pharmacological reduction of TXNIP expression is capable of promoting cardiomyocyte survival.
Verapamil reduces TXNIP and apoptosis in the diabetic heart. To further test whether verapamil is also capable of reducing proapoptotic TXNIP in the face of diabetes, we again rendered wild-type mice diabetic with STZ and treated them with or without verapamil. Although both groups developed severe diabetes and there was no significant difference in their blood glucose (Ͼ400 mg/dl), verapamil-treated mice showed significantly lower levels of TXNIP and cleaved caspase-3 expression in their hearts (Fig. 6, A and B) . We also compared the effects of STZ in the absence or presence of verapamil. Interestingly, although STZ-induced diabetes still increased cardiac TXNIP and cleaved caspase-3 expression compared with the very low levels in mice treated with verapamil only, verapamil prevented any increase beyond the levels observed in nondiabetic control mice (Fig. 6, C and D) and thereby led to a complete normalization of these parameters even in the face of severe diabetes. These protective effects of verapamil became even more apparent when we directly assessed apoptosis by TUNEL, demonstrating a Ͼ10-fold increase in apoptotic nuclei in diabetic hearts that was almost completely blunted by verapamil (Fig. 7) .
DISCUSSION
The results of the present study demonstrate that cardiac TXNIP expression is increased in STZ-and obesity-induced diabetes and associated with increased cardiomyocyte apoptosis. This is consistent with our previous findings in pancreatic beta cells and the role of TXNIP as a proapoptotic factor (18, 29) . Furthermore, it suggests that TXNIP may be involved in the pathogenesis of diabetic cardiomyopathy in which cardiomyocyte apoptosis represents a key mechanism (9, 10, 28) . Recently, TXNIP has also been implicated in cardiomyocyte damage associated with MI, and inhibition of TXNIP was suggested as a potential cardioprotective approach on the basis of knockdown experiments (31). Moreover, in vivo studies in cardiomyocyte-specific TXNIP knockout mice revealed reduced cardiac hypertrophy in response to pressure overload (34) . On the basis of these collective data, TXNIP emerged as an attractive therapeutic target for a variety of cardiovascular disorders, but feasible inhibitors remained elusive.
Our findings now reveal for the first time that calcium channel blockers (and in particular verapamil) can act as potent TXNIP inhibitors and can reduce cardiac TXNIP expression and apoptosis even in the face of severe diabetes. These approved agents (widely used as antihypertensive drugs) thereby may represent a readily available pharmacological tool to achieve the desired TXNIP inhibition and cardioprotection.
Our results indicate that the observed calcium channel blocker effects on TXNIP expression occur at the transcriptional level and indeed calcium has been found to control several transcriptional regulators such as CREB, DREAM, MEF2, NFAT, and NF-B (16) . Interestingly, analysis with the Genomatix software revealed that TXNIP does contain putative binding sites for most of them, and CREB and NF-B have been shown to be also involved in glucose sensing (8, 12) and diabetic cardiomyopathy (35) , suggesting that the calcium channel blocker effects may be mediated by a complicated signaling network. Studies to unravel this network and identify the critical transcription factors are currently ongoing.
Despite some controversy in the past (17) , large patient studies have demonstrated that calcium channel blockers are effective in reducing the mortality and morbidity of cardiovascular disease (21, 23) and verapamil has been shown to have beneficial effects especially in diabetic cardiomyopathy (1) . Given the increased TXNIP expression and apoptosis we observed in diabetic hearts and the TXNIP-lowering antiapoptotic capacity of verapamil revealed in the present study, this further supports the notion that inhibition of cardiac TXNIP expression (e.g., by verapamil) may help treat and/or prevent diabetic cardiomyopathy. In addition, calcium channel blockers have previously been shown to have protective, antioxidant effects in the cardiovascular system (15) and our results suggest that some of these effects might be mediated by TXNIP reduction. In fact, decreased TXNIP expression has also been shown to be part of the antioxidant effects of nitric oxide (24) . Moreover, TXNIP deficiency in the HcB-19 mice mimicked the beneficial effects of calcium channel blocker in terms of reduction in apoptotic factors. However, we cannot exclude the possibility that some of the protective effects observed with verapamil are independent of its TXNIP-lowering capacity and are based on the reduction of intracellular calcium levels and/or other factors.
Finally, our findings of decreased apoptosis in TXNIPdeficient hearts underline the importance of TXNIP as a potential target for cardioprotection, be it through calcium channel blockers or by novel agents designed to specifically inhibit cardiac TXNIP expression. Thus, although additional clinical studies are necessary, reducing TXNIP, e.g., by calcium channel blockers, may provide a novel approach to promote cardiomyocyte survival and cardiac function, especially in diabetes.
